Paradigm in the news

 
Paradigm Careers
02.16.17

Paradigm Diagnostics Announces $7M Series B Financing

[Phoenix, AZ and New York, NY – February 16, 2017] – Paradigm Diagnostics today announced the near completion of their $7M Series B financing, adding an additional $3M from New Sciences Ventures on top of the $3.5M led by Mesa Verde Venture Partners and other strategic partners at the end of 2016. These resources will […]

Read more
 
 
Paradigm Careers
11.16.16

Paradigm Diagnostics Announces Initial Closing of $7M Series B Financing

Syndicate Includes Leading Venture and Strategic Investors; Proceeds to Support Research Collaborations and the Rapid Commercialization of the Paradigm Cancer Diagnostic Test – PCDx™ [Phoenix, AZ, November 16, 2016] — Paradigm Diagnostics today announced the first closing of a $7 million Series B financing to support the rapid commercial expansion of its PCDx tumor sequencing […]

Read more
 
 
Paradigm Careers
07.15.16

Independent Clinical Study Published Demonstrating Clinical Utility of the Paradigm Cancer Diagnostic (PCDx) Test

[PHOENIX, AZ, July 15, 2016]— An independent, peer-reviewed clinical study published today in Oncotarget entitled “Clinical Benefit of A Precision Medicine Based Approach For Guiding Treatment of Refractory Cancers” provides additional data supporting the clinical utility of the Paradigm PCDx test to significantly help improve outcomes for patients with cancer. This independent study was performed […]

Read more
 
 
Paradigm Careers
06.30.16

Paradigm and IDB Resources Announce Exclusive PCDx Tumor Profiling Service Agreement

Expands Global Distribution Of Cancer Testing Service to Southeast Asia [PHOENIX, AZ and PETALING JAYA, MALAYSIA, June 30, 2016]– Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with IDB Resources to enable patient access […]

Read more
 
 
Paradigm Careers
05.18.16

Paradigm and CORE Diagnostics, India Announce Exclusive PCDx Tumor Profiling Service Agreement

[PHOENIX, AZ and NEW DELHI, INDIA, May 18, 2016]– Paradigm, a molecular information & Next Generation Sequencing (NGS) corporation specializing in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with CORE Diagnostics to facilitate patient access to its cancer profiling service, PCDx, in India. Given […]

Read more
 
 
Paradigm Careers
11.09.15

Paradigm Leadership and TCGA Publish Study on Comprehensive Genomic Analysis of Primary Prostate Tumors in Cell

Paradigm Leadership played key leadership roles in a recently published study analyzing genomic changes in primary prostate tumors that has provided the most comprehensive and integrated view of gene changes for prostate cancer to date. In this National Institute of Health-funded, The Cancer Genome Atlas (TCGA) project, Paradigm leveraged experience and expertise from The International […]

Read more
 
 
Paradigm Careers
11.05.15

Paradigm Leadership Plays Significant Role on Study Published in NEJM Defining the Genetic Basis of Papillary Renal-Cell Carcinoma

Paradigm’s Executive Team has provided key leadership and expertise in a study to define genomic changes in papillary renal-cell carcinoma that has provided the most comprehensive and integrated view of gene changes for kidney cancer to date. Conventional evaluation characterizes papillary renal-cell carcinoma as a heterogeneous disease constituting various types of renal cancer; however, precious […]

Read more
 
 
Paradigm Careers
09.24.15

Genomic Profiling Study Brings Personalized Medicine to Metastatic Bladder Cancer Patients

Bethesda, MD – September 24, 2015 — The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center. This prospective study is the first project of the Bladder Cancer Genomics Consortium (BCGC), […]

Read more
 
 
Paradigm Careers
08.19.15

Paradigm Announces Molecular Profiling Collaboration for Study of Altiratinib In Genomically Defined Cancer Patients

Collaboration designed to assess key molecular targets associated for phase I clinical trial [ANN ARBOR, MI and PHOENIX, AZ, August 19, 2015] Paradigm today announced a pharmaceutical services relationship with Deciphera Pharmaceuticals for a phase I clinical study of Altiratinib in molecularly defined cancers driven by either MET or TRK genomic alterations including lung cancer, […]

Read more
 
 
Paradigm Careers
08.07.15

Paradigm Expands Access to PCDX Personalized Medicine Service by Signing Contract with Three Rivers Provider Network

Paradigm Cancer Diagnostic (PCDxTM) test now accessible to an additional 15 Million covered lives in US [Ann Arbor, MI and Phoenix, AZ, August 7, 2015]– Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, has signed an agreement with health insurer Three Rivers Provider Network, Inc., […]

Read more
 

Start getting better results, faster.

Order PCDx